License

Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates

Retrieved on: 
Mittwoch, Mai 8, 2024
Corporation, FDA, Society, EAP, Sale, Celiprolol, Acer, Investment, Priority review, NDA, Conference call, Research, Sleep, License, Conference, Discover, Idiopathic hypersomnia, Disease, Exercise, IH, PDUFA, Patient, Acquisition, Physician, NPC, UCD, Caregiver, Therapy, Pharmaceutical industry

CELEBRATION, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today provided corporate updates and reported its financial results for the first quarter ended March 31, 2024. 

Key Points: 
  • ET
    CELEBRATION, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today provided corporate updates and reported its financial results for the first quarter ended March 31, 2024.
  • Zevra has seen a meaningful increase in reimbursement coverage, reaching nearly 75% of covered lives as of May 1, 2024.
  • Overview of Q1 2024 Financial Results:
    Net revenue for Q1 2024 was $3.4 million, compared to net revenue of $3.2 million in Q1 2023.
  • ET, to discuss its corporate and financial results for Q1 2024.

Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Dienstag, Mai 7, 2024
Corporation, Sale, Greyhawk, License, Ribociclib, Palsy, HER2, General counsel, NVS, Food, ARVN, Research, Quantum Leap, Business development, Genentech, Development, Administration, Arm, Prostate cancer, Exercise, CDK7, Senior, Patient, Bayer, EOP, CDK4, Interim, PROTAC, LRRK2, Pharmaceutical industry

NEW HAVEN, Conn., May 07, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the first quarter ended March 31, 2024 and provided a corporate update.

Key Points: 
  • Announced the resignation of Chief Financial Officer and Treasurer, Sean Cassidy, effective February 29, 2024.
  • Research and Development Expenses: Research and development expenses were $84.3 million for the quarter ended March 31, 2024, as compared with $95.3 million for the quarter ended March 31, 2023.
  • General and Administrative Expenses: General and administrative expenses were $24.3 million for the quarter ended March 31, 2024, as compared with $24.9 million for the quarter ended March 31, 2023.
  • Revenues: Revenues were $25.3 million for the quarter ended March 31, 2024 as compared with $32.5 million for the quarter ended March 31, 2023.

Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events

Retrieved on: 
Donnerstag, Mai 9, 2024
Biotechnology, General Health, Pharmaceutical, Health, Graves' ophthalmopathy, Investment, Research, Teprotumumab, License, Partnership, Webcast, TRX, Patient, Glucagon, Access, TED, Amgen, Pharmaceutical industry

Keveyis®: First quarter net revenue remained very strong at $13.1 million – an increase of approximately 3% compared to the same period in 2023.

Key Points: 
  • Keveyis®: First quarter net revenue remained very strong at $13.1 million – an increase of approximately 3% compared to the same period in 2023.
  • Recorlev®: First quarter net revenue was $10.6 million – an increase of $6.1 million compared to the same period in 2023.
  • Cash, cash equivalents, and short-term investments at March 31, 2024 was $87.4 million compared to $72.5 million at December 31, 2023.
  • Xeris will host a conference call and webcast on Thursday, May 9, 2024 at 8:30 a.m. Eastern Time.

Prothena Reports First Quarter 2024 Financial Results and Business Highlights

Retrieved on: 
Mittwoch, Mai 8, 2024
Research, Finance, Clinical Trials, Professional Services, Cardiology, Biotechnology, Pharmaceutical, Health, Science, Oncology, Amyloid, Mortality, FDA, License, Fast Track, TTR, ATTR, Organ dysfunction, Risk, Food, Amyloidosis, Orphan, Epitope, Partnership, IND, Roche, Culture, Therapy, Novo Nordisk, Patient, Acquisition, Failure, VITAL, Bristol Myers Squibb, Clinical trial, European Medicines Agency, Overalls, Pharmaceutical industry

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the first quarter of 2024 and provided business highlights.

Key Points: 
  • Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the first quarter of 2024 and provided business highlights.
  • For the first quarter of 2024, Prothena reported a net loss of $72.2 million, as compared to a net loss of $46.9 million for the first quarter of 2023, respectively.
  • Prothena reported total revenue of $0.1 million for the first quarter of 2024, as compared to total revenue of $2.2 million for the first quarter of 2023.
  • Research and development (R&D) expenses totaled $64.1 million for the first quarter of 2024, as compared to $44.8 million for the first quarter of 2023.

Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids

Retrieved on: 
Mittwoch, Mai 8, 2024
General Health, Cannabis, Pharmaceutical, Oncology, Consumer, Mental Health, Natural Resources, Public Policy, Biotechnology, Women, Alternative Medicine, Health, Government, License, Cancer, HHS, Breast cancer, Woman, Addiction, Schedule, Breast, Congress, Depression, History, Therapy, Patent, Patient, Licensee, Cannabinoid, Anxiety, Pharmaceutical industry

In an historic move on Tuesday April 30, 2024, the Biden administration moved to reschedule marijuana, one source of cannabinoids, as a Schedule III controlled substance.

Key Points: 
  • In an historic move on Tuesday April 30, 2024, the Biden administration moved to reschedule marijuana, one source of cannabinoids, as a Schedule III controlled substance.
  • Enveric applauds the move by the Biden administration which enjoys bi-partisan Congressional support and advances the development of medical uses of much needed drugs.
  • “We look forward to partnering with the Licensee and are confident in their leadership to translate these discoveries into promising treatments for cancer patients.
  • The licensed methods also apply to many other forms of cancer that afflict millions more patients in the US.

Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates

Retrieved on: 
Montag, Mai 6, 2024
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, The Association, License, ADOA, Dravet syndrome, Cognition, MECP2, SYNGAP1, RNA, Rett syndrome, Acadia Pharmaceuticals, Cell, Conference, Seizure, CNS, Therapy, OLE, Patient, Gene, Society, Medicine, Collaboration, Central nervous system, Behavior, ARVO, Pharmaceutical industry

“In the first quarter of 2024, Stoke took a major step forward in our effort to advance the first potential disease-modifying medicine for patients with Dravet syndrome,” said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics.

Key Points: 
  • “In the first quarter of 2024, Stoke took a major step forward in our effort to advance the first potential disease-modifying medicine for patients with Dravet syndrome,” said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics.
  • These data showed substantial and durable reductions in seizures and clinically meaningful improvements in multiple measures of cognition and behavior that support the potential for disease modification.
  • The Company expanded and strengthened its management team with the appointments of Jason Hoitt as Chief Commercial Officer and Thomas (Tommy) Leggett as Chief Financial Officer.
  • General and administrative expenses for the three months ended March 31, 2024 were $10.2 million, compared to $10.2 million for the same period in 2023.

Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics

Retrieved on: 
Montag, Mai 6, 2024
Biotechnology, Diabetes, Health, Pharmaceutical, Health Technology, Multimedia, License, Partnership, Glucagon, Insulin, Bionics, Pharmaceutical industry

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into an exclusive worldwide collaboration and license agreement with Beta Bionics, Inc. for the development and commercialization of a glucagon product utilizing Xeris’ XeriSol™ technology for use in Beta Bionics’ proprietary bi-hormonal pump and pump systems.

Key Points: 
  • Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into an exclusive worldwide collaboration and license agreement with Beta Bionics, Inc. for the development and commercialization of a glucagon product utilizing Xeris’ XeriSol™ technology for use in Beta Bionics’ proprietary bi-hormonal pump and pump systems.
  • View the full release here: https://www.businesswire.com/news/home/20240506079856/en/
    “We’re excited to be partnering with Beta Bionics by being the exclusive provider of the glucagon component that will facilitate their development of the first dual-hormone pump for people with diabetes,” said Paul R. Edick, Chairman and CEO of Xeris.
  • “We will move quickly to support Beta Bionics in this important development program.”
    “If insulin is like the gas pedal in your car, then glucagon is the brakes,” said Sean Saint, CEO of Beta Bionics.
  • “Beta Bionics has always felt that a bi-hormonal glucose control system has real advantages over insulin alone…just like the brakes in your car.

Local Segway Tour Company, HumanOnaStick, to Manufacture Redesigned Segway 2.0

Retrieved on: 
Mittwoch, Mai 8, 2024
License, Safety, City, Personal, Sound, Mobile entertainment, Minneapolis–Saint Paul, Tourism

MINNEAPOLIS, May 8, 2024 /PRNewswire/ -- Minneapolis-based Segway tour agency, Mobile Entertainment, LLC, is set to offer safer tours utilizing the technologically enhanced Segway 2.0.

Key Points: 
  • MINNEAPOLIS, May 8, 2024 /PRNewswire/ -- Minneapolis-based Segway tour agency, Mobile Entertainment, LLC, is set to offer safer tours utilizing the technologically enhanced Segway 2.0.
  • Building on the original Segway design, Segway 2.0 features improved safety and an enhanced riding experience through its Swarm Navigation Technology.
  • With a proven business model ready for scaling, HumanOnaStick is preparing to go global, offering the franchise model to national and international markets.
  • Immersive Sound and Lighting Enhancements: The redesigned Segway 2.0 is equipped with premium sound, touch display and an automatic lighting system.

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024

Retrieved on: 
Mittwoch, Mai 1, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Doctor of Philosophy, PFS, Paranal Observatory, Table, License, Summit, Investment, ELCC, Progression-free survival, Research, Intraparenchymal hemorrhage, Immunotherapy, Trial of the century, Webcast, Cohort, Forecasting, PD-1, NGS, TKI, Patient, GRAIL, Brain, SMMT, Neoplasm, EGFR, VEGF, GAAP, Royal institute, Neuro, Lung cancer, Pharmaceutical industry

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2024.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2024.
  • In January 2024, followed by a presentation at ELCC 2024 in March 2024, Akeso announced updates from its Phase II AK112-201 trial data.
  • Also at ELCC 2024, Summit and Akeso highlighted promising ivonescimab Phase II data in NSCLC patients with brain metastases.
  • Operating cash outflow for the three months ended March 31, 2024 and 2023 was $30.1 million and $13.1 million, respectively.

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer

Retrieved on: 
Donnerstag, April 11, 2024
Sale, License, NVS, ARVN, Goldman Sachs, Research, Prostate cancer, Patient, PROTAC, Pharmaceutical industry

NEW HAVEN, Conn., April 11, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it has entered into an exclusive strategic license agreement with Novartis (NYSE: NVS) for the worldwide development and commercialization of ARV-766, Arvinas’ second generation PROTAC® androgen receptor (AR) degrader for patients with prostate cancer. The transaction also includes an asset purchase agreement for the sale of Arvinas’ preclinical AR-V7 program to Novartis.

Key Points: 
  • The transaction also includes an asset purchase agreement for the sale of Arvinas’ preclinical AR-V7 program to Novartis.
  • “We believe the expertise and scale of Novartis will broaden the development of ARV-766 and its potential to be a first- and best-in-class treatment for patients with prostate cancer.
  • Under the License Agreement, Arvinas is eligible to receive additional development, regulatory, and commercial milestones of up to $1.01 billion, as well as tiered royalties for ARV-766.
  • Goldman Sachs & Co. LLC is acting as the exclusive financial advisor to Arvinas.